| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding | |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | Entrez:7422 MIM:192240 HGNC:HGNC:12680 Ensembl:ENSG00000112715 AllianceGenome:HGNC:12680 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | vascular endothelial growth factor A | |||||
| GTO ID | GTC1224 |
| Trial ID | NCT00088283 |
| Disease | Retinal Vein Occlusion |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO |
| Year | 2004 |
| Country | United States |
| Company sponsor | Eyetech Pharmaceuticals |
| Other ID(s) | EOP 1011B |
| Cohort1: pegaptanib_dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: pegaptanib_dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: sham | |||||||||||
|
|||||||||||